基于两性霉素B的疗法治疗中枢神经系统曲霉菌病疗效不佳。
Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
作者信息
Schwartz Stefan, Ruhnke Markus, Ribaud Patricia, Reed Elizabeth, Troke Peter, Thiel Eckhard
机构信息
Medizinische Klinik III, Charité Campus Benjamin Franklin, Freie Universität, Berlin, Germany.
出版信息
Mycoses. 2007 May;50(3):196-200. doi: 10.1111/j.1439-0507.2007.01345.x.
Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.
最近，有报道称伏立康唑联合神经外科手术治疗中枢神经系统（CNS）曲霉菌病的患者反应率和生存率有所提高。我们回顾性评估了17例确诊或疑似CNS曲霉菌病患者的治疗结果，这些患者单独接受两性霉素B治疗（n = 15），或联合5-氟胞嘧啶（n = 3）或伊曲康唑（n = 2）治疗。4例患者接受了神经外科手术。首发症状或CNS曲霉菌病首次影像学证据出现后，死亡率为100%，中位生存期仅为10天（范围：3 - 60天）。总之，两性霉素B和伊曲康唑治疗CNS曲霉菌病的疗效微乎其微。
Zotero 插件